Clinical trials for MRI scan

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to MRI scan. For all clinical trials, go to clinical trials search

This list shows clinical trials for MRI scan

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • MRI scan
Title Recruitment status Location
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY Arabia Saudi
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY Argentina
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY Australia
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY Austria
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY Brazil
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY Canada
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY China
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY Colombia
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY Czech Republic
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE III STUDY OF RAD001 ADJUVANT THERAPY IN POOR RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) OF RAD001 VERSUS MATCHING PLACEBO AFTER PATIENTS HAVE ACHIEVED COMPLETE RESPONSE WITH FIRST-LINE RITUXIMAB-CHEMOTHERAPY Egypt

Page last reviewed: 07/10/2024

Next review due: 01/10/2024